Kalaris Therapeutics Inc
KLRS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.46 | 0.01 | 0.03 | 0.01 |
| FCF Yield | -10.65% | -29.81% | -22.86% | 0.00% |
| EV / EBITDA | -5.65 | 3.39 | 7.82 | 3.97 |
| Quality | ||||
| ROIC | -16.88% | -14.39% | -10.79% | -17.23% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.95 | 1.31 | 0.73 | 0.11 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 22.63% | -100.04% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 3.43 | 7.79 | 11.53 | 6.48 |
| Interest Coverage | 0.00 | 0.00 | -7.18 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |